New Pappas Capital Fund Makes First Investment
Research Triangle Park, NC, May 24, 2017 – Pappas Capital, a life science venture capital firm, announced today that its new fund, Pappas Ventures V, recently invested in OrphoMed, a clinical stage company that is developing best-in-class therapies for treatment of inadequately-controlled gastrointestinal disorders. The investment in OrphoMed is the first investment by the new Pappas Ventures fund.
© 2018 Pappas Capital, LLC. ALL RIGHTS RESERVED.